Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Alector doses first patient in Phase 2 study of AL001 in ALS » 08:44
09/09/21
09/09
08:44
09/09/21
08:44
ALEC

Alector

$21.65 /

-5.08 (-19.00%)

, GSK

GlaxoSmithKline

$40.52 /

-0.42 (-1.03%)

Alector (ALEC) has dosed…

Alector (ALEC) has dosed the first participant in a Phase 2 clinical study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of AL001 in people with amyotrophic lateral sclerosis who carry a C9orf72 mutation. AL001 is being developed in collaboration with GlaxoSmithKline (GSK). AL001 is a potential first-in-class monoclonal antibody designed to elevate progranulin, a key regulator of immune activity in the brain. The Phase 2 trial of AL001 is expected to enroll approximately 45 adult participants with C9orf72-associated ALS. The primary endpoint of the study is safety, tolerability, pharmacokinetics and pharmacodynamics of AL001, including plasma and cerebrospinal fluid progranulin levels. Taken together, these data are intended to inform trial design and dosing for future efficacy studies of AL001 in ALS.

ShowHide Related Items >><<
GSK GlaxoSmithKline
$40.52 /

-0.42 (-1.03%)

ALEC Alector
$21.65 /

-5.08 (-19.00%)

ALEC Alector
$21.65 /

-5.08 (-19.00%)

09/08/21 Stifel
Alector departures a surprise, but not much to read into, says Stifel
09/08/21 Goldman Sachs
Alector leadership changes 'come as a surprise,' says Goldman Sachs
07/30/21 H.C. Wainwright
Alector selloff on AL001 readout surprising, says H.C. Wainwright
07/06/21 Citi
Alector price target raised to $43 from $31 at Citi
GSK GlaxoSmithKline
$40.52 /

-0.42 (-1.03%)

08/26/21 UBS
GlaxoSmithKline price target raised to 1,540 GBp from 1,485 GBp at UBS
08/20/21 JPMorgan
GlaxoSmithKline price target raised to 1,500 GBp from 1,300 GBp at JPMorgan
08/19/21 Berenberg
GlaxoSmithKline price target raised to 1,625 GBp from 1,570 GBp at Berenberg
08/18/21 Wedbush
AnaptysBio price target raised to $25 from $20 at Wedbush
GSK GlaxoSmithKline
$40.52 /

-0.42 (-1.03%)

ALEC Alector
$21.65 /

-5.08 (-19.00%)

GSK GlaxoSmithKline
$40.52 /

-0.42 (-1.03%)

GSK GlaxoSmithKline
$40.52 /

-0.42 (-1.03%)

ALEC Alector
$21.65 /

-5.08 (-19.00%)

GSK GlaxoSmithKline
$40.52 /

-0.42 (-1.03%)

Hot Stocks
Alector doses first patient in Phase 2 study of AL001 in ALS » 08:44
09/09/21
09/09
08:44
09/09/21
08:44
ALEC

Alector

$21.65 /

-5.08 (-19.00%)

, GSK

GlaxoSmithKline

$40.52 /

-0.42 (-1.03%)

Alector (ALEC) has dosed…

Alector (ALEC) has dosed the first participant in a Phase 2 clinical study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of AL001 in people with amyotrophic lateral sclerosis who carry a C9orf72 mutation. AL001 is being developed in collaboration with GlaxoSmithKline (GSK). AL001 is a potential first-in-class monoclonal antibody designed to elevate progranulin, a key regulator of immune activity in the brain. The Phase 2 trial of AL001 is expected to enroll approximately 45 adult participants with C9orf72-associated ALS. The primary endpoint of the study is safety, tolerability, pharmacokinetics and pharmacodynamics of AL001, including plasma and cerebrospinal fluid progranulin levels. Taken together, these data are intended to inform trial design and dosing for future efficacy studies of AL001 in ALS.

ShowHide Related Items >><<
GSK GlaxoSmithKline
$40.52 /

-0.42 (-1.03%)

ALEC Alector
$21.65 /

-5.08 (-19.00%)

ALEC Alector
$21.65 /

-5.08 (-19.00%)

09/08/21 Stifel
Alector departures a surprise, but not much to read into, says Stifel
09/08/21 Goldman Sachs
Alector leadership changes 'come as a surprise,' says Goldman Sachs
07/30/21 H.C. Wainwright
Alector selloff on AL001 readout surprising, says H.C. Wainwright
07/06/21 Citi
Alector price target raised to $43 from $31 at Citi
GSK GlaxoSmithKline
$40.52 /

-0.42 (-1.03%)

08/26/21 UBS
GlaxoSmithKline price target raised to 1,540 GBp from 1,485 GBp at UBS
08/20/21 JPMorgan
GlaxoSmithKline price target raised to 1,500 GBp from 1,300 GBp at JPMorgan
08/19/21 Berenberg
GlaxoSmithKline price target raised to 1,625 GBp from 1,570 GBp at Berenberg
08/18/21 Wedbush
AnaptysBio price target raised to $25 from $20 at Wedbush
GSK GlaxoSmithKline
$40.52 /

-0.42 (-1.03%)

ALEC Alector
$21.65 /

-5.08 (-19.00%)

GSK GlaxoSmithKline
$40.52 /

-0.42 (-1.03%)

GSK GlaxoSmithKline
$40.52 /

-0.42 (-1.03%)

ALEC Alector
$21.65 /

-5.08 (-19.00%)

GSK GlaxoSmithKline
$40.52 /

-0.42 (-1.03%)

Recommendations
Alector departures a surprise, but not much to read into, says Stifel » 09:58
09/08/21
09/08
09:58
09/08/21
09:58
ALEC

Alector

$22.82 /

-3.91 (-14.63%)

Stifel analyst Paul…

Stifel analyst Paul Matteis says Alector's (ALEC) announcement last night that its Chief Operating Officer Shehnaaz Suliman and Chief Medical Officer Robert Paul will be stepping down comes as a surprise. However, Alector CEO Arnon Rosenthal is staying and the recent GlaxoSmithKline (GSK) deal gives the company "plenty of runway to continue executing on their pipeline," Matteis tells investors in a research note. Management told the analyst the transition is amicable and noted that Dr. Paul prefers a smaller organization and Dr. Suliman may pursue a CEO role. While the optics aren't great, the news "doesn't seem like there's much to read into," says Matteis, who keeps a Buy rating on Alector. The stock in morning trading is down 18% to $21.98.

ShowHide Related Items >><<
ALEC Alector
$22.82 /

-3.91 (-14.63%)

ALEC Alector
$22.82 /

-3.91 (-14.63%)

09/08/21 Goldman Sachs
Alector leadership changes 'come as a surprise,' says Goldman Sachs
07/30/21 H.C. Wainwright
Alector selloff on AL001 readout surprising, says H.C. Wainwright
07/06/21 Citi
Alector price target raised to $43 from $31 at Citi
07/02/21 Goldman Sachs
GSK collaboration 'positive' for Alector, says Goldman Sachs
ALEC Alector
$22.82 /

-3.91 (-14.63%)

ALEC Alector
$22.82 /

-3.91 (-14.63%)

Recommendations
Alector leadership changes 'come as a surprise,' says Goldman Sachs » 09:57
09/08/21
09/08
09:57
09/08/21
09:57
ALEC

Alector

$22.89 /

-3.84 (-14.37%)

After Alector (ALEC)…

After Alector (ALEC) announced senior executive leadership changes, including Chief Operating Officer Dr. Shehnaaz Suliman and Chief Medical Officer Dr. Robert Paul leaving the company by year-end, Goldman Sachs analyst Graig Suvannavejh said the changes "come as a surprise to us" and he would not be surprised to see share weakness at the market open. However, management stated that completion of the company's recent $2.2B deal with GlaxoSmithKline (GSK) allowed it to "naturally next focus on near- and longer-term goals." With Alector expected to quickly expand its immuno-neurology and immuno-oncology pipeline efforts, the company will now look for a CMO candidate with larger pharmaceutical company experience, added Suvannavejh, who continues to be positive on the longer term story. He keeps a Buy rating on the shares with a 12-month price target of $33.

ShowHide Related Items >><<
ALEC Alector
$22.89 /

-3.84 (-14.37%)

ALEC Alector
$22.89 /

-3.84 (-14.37%)

07/30/21 H.C. Wainwright
Alector selloff on AL001 readout surprising, says H.C. Wainwright
07/06/21 Citi
Alector price target raised to $43 from $31 at Citi
07/02/21 Goldman Sachs
GSK collaboration 'positive' for Alector, says Goldman Sachs
ALEC Alector
$22.89 /

-3.84 (-14.37%)

ALEC Alector
$22.89 /

-3.84 (-14.37%)

Hot Stocks
Alector announces top management changes » 16:33
09/07/21
09/07
16:33
09/07/21
16:33
ALEC

Alector

$26.72 /

+0.07 (+0.26%)

Alector announced that…

Alector announced that Shehnaaz Suliman, and Robert Paul will be stepping down from their respective roles as President and COO and Chief Medical Officer. Each will continue to serve for a transition period and plan to remain available as advisors until the end of 2021. Sam Jackson, Senior Vice President, Clinical Sciences, will assume the role of interim Chief Medical Officer. Jackson is an established leader with more than 15 years of experience leading clinical development functions. He joined Alector in 2020 and among his primary responsibilities is the development of AL001, which is currently in Phase 3 clinical testing for the treatment of frontotemporal dementia. Suliman joined Alector in 2019 and provided strategic and operational leadership while overseeing the company's early development, portfolio, business development, finance, investor relations, legal and administrative functions. Robert Paul joined Alector in 2016 and has been responsible for advancing all four of Alector's immuno-neurology programs into the clinic and laying the foundation for the company's overarching development strategy. Sam Jackson, joined Alector as the Senior Vice President of Clinical Development in 2020 bringing more than 15 years of industry experience leading clinical development for novel neurologic, immunologic and ophthalmic programs.

ShowHide Related Items >><<
ALEC Alector
$26.72 /

+0.07 (+0.26%)

ALEC Alector
$26.72 /

+0.07 (+0.26%)

07/30/21 H.C. Wainwright
Alector selloff on AL001 readout surprising, says H.C. Wainwright
07/06/21 Citi
Alector price target raised to $43 from $31 at Citi
07/02/21 Goldman Sachs
GSK collaboration 'positive' for Alector, says Goldman Sachs
06/07/21 Goldman Sachs
Goldman says Biogen approval has positive read to Alector, Athira
ALEC Alector
$26.72 /

+0.07 (+0.26%)

ALEC Alector
$26.72 /

+0.07 (+0.26%)

Over a month ago
Earnings
Alector reports Q2 EPS (69c), consensus (69c) » 17:11
08/03/21
08/03
17:11
08/03/21
17:11
ALEC

Alector

$25.75 /

+0.39 (+1.54%)

Reports Q2 revenue…

Reports Q2 revenue $6.57M, consensus $8.73M. "With the recent presentation of encouraging Phase 2 data for our lead program, AL001 in people with FTD-GRN, at the Alzheimer's Association International Conference and our announcement of a significant collaboration with GlaxoSmithKline to expand and accelerate the development of AL001 and AL101, we move much closer to realizing the vast potential of our progranulin franchise programs," said Arnon Rosenthal, Ph.D., co-founder and chief executive officer of Alector. "Our earlier-stage pipeline is also steadily progressing and based on our immuno-neurology expertise and insights into human genetics, we continue working to advance new programs to the clinic, all with the aim of halting the degeneration associated with serious neurological disease."

ShowHide Related Items >><<
ALEC Alector
$25.75 /

+0.39 (+1.54%)

ALEC Alector
$25.75 /

+0.39 (+1.54%)

07/30/21 H.C. Wainwright
Alector selloff on AL001 readout surprising, says H.C. Wainwright
07/06/21 Citi
Alector price target raised to $43 from $31 at Citi
07/02/21 Goldman Sachs
GSK collaboration 'positive' for Alector, says Goldman Sachs
06/07/21 Goldman Sachs
Goldman says Biogen approval has positive read to Alector, Athira
ALEC Alector
$25.75 /

+0.39 (+1.54%)

ALEC Alector
$25.75 /

+0.39 (+1.54%)

Recommendations
Alector selloff on AL001 readout surprising, says H.C. Wainwright » 06:18
07/30/21
07/30
06:18
07/30/21
06:18
ALEC

Alector

$24.06 /

-6.43 (-21.09%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Andrew Fein reiterates a Buy rating on Alector with a $41 price target saying he was surprised by yesterday's selloff in the shares following the Phase 2 data readout of AL001. Had Alector positioned the expectations based on the clinical endpoint data, investors may have reacted differently, Fein tells investors in a research note. A "three-point change" in the AL001 treatment arm speaks of the "robust" mechanism of action of the drug, says the analyst. Fein views the Phase 2 data as "encouraging."

ShowHide Related Items >><<
ALEC Alector
$24.06 /

-6.43 (-21.09%)

ALEC Alector
$24.06 /

-6.43 (-21.09%)

07/06/21 Citi
Alector price target raised to $43 from $31 at Citi
07/02/21 Goldman Sachs
GSK collaboration 'positive' for Alector, says Goldman Sachs
06/07/21 Goldman Sachs
Goldman says Biogen approval has positive read to Alector, Athira
01/15/21 BofA
Alector reinstated with a Buy at BofA
ALEC Alector
$24.06 /

-6.43 (-21.09%)

ALEC Alector
$24.06 /

-6.43 (-21.09%)

Conference/Events
Alector to ho ld a conference call » 12:55
07/29/21
07/29
12:55
07/29/21
12:55
ALEC

Alector

$27.06 /

-3.43 (-11.25%)

Management reviews the…

Management reviews the AL001 Phase 2 results as discussed at the recently-held Alzheimer's International Conference on a conference call to be held on July 29 at 1 pm. Webcast Link

ShowHide Related Items >><<
ALEC Alector
$27.06 /

-3.43 (-11.25%)

ALEC Alector
$27.06 /

-3.43 (-11.25%)

07/06/21 Citi
Alector price target raised to $43 from $31 at Citi
07/02/21 Goldman Sachs
GSK collaboration 'positive' for Alector, says Goldman Sachs
06/07/21 Goldman Sachs
Goldman says Biogen approval has positive read to Alector, Athira
01/15/21 BofA
Alector reinstated with a Buy at BofA
ALEC Alector
$27.06 /

-3.43 (-11.25%)

ALEC Alector
$27.06 /

-3.43 (-11.25%)

Hot Stocks
Alector says AL001 slowed progression of dementia by 47% in study » 10:15
07/29/21
07/29
10:15
07/29/21
10:15
ALEC

Alector

$29.54 /

-0.95 (-3.12%)

Alector presented results…

Alector presented results from the company's INFRONT-2 Phase 2 clinical trial of AL001 at the Alzheimer's Association International Conference. AL001 is initially being developed for the treatment of adults at risk for or with symptomatic frontotemporal dementia due to a progranulin gene mutation. Data presented today focused on up to twelve symptomatic FTD-GRN patients treated over twelve months in an open-label study designed to assess safety, pharmacokinetics and pharmacodynamics, exploratory biomarkers and efficacy, the company said. It added, "AL001 showed a favorable safety profile and rapidly restored progranulin levels to normal ranges in both plasma and cerebrospinal fluid for the duration of treatment. While the INFRONT-2 Phase 2 study was not designed to demonstrate clinical benefit, clinical outcome assessments using the CDR plus NACC FTLD-SB scale found that AL001 treatment slowed clinical progression by 47% compared to a matched control cohort of participants from the Genetic FTD Initiative. Additionally, multiple disease-relevant biomarkers of lysosomal function, complement activation and neuronal health trended toward normalization or remained stable." Alector added that it is actively enrolling the INFRONT-3 Phase 3 pivotal clinical study of AL001 in at-risk and symptomatic carriers of the progranulin mutation causative of FTD.

ShowHide Related Items >><<
ALEC Alector
$29.54 /

-0.95 (-3.12%)

ALEC Alector
$29.54 /

-0.95 (-3.12%)

07/06/21 Citi
Alector price target raised to $43 from $31 at Citi
07/02/21 Goldman Sachs
GSK collaboration 'positive' for Alector, says Goldman Sachs
06/07/21 Goldman Sachs
Goldman says Biogen approval has positive read to Alector, Athira
01/15/21 BofA
Alector reinstated with a Buy at BofA
ALEC Alector
$29.54 /

-0.95 (-3.12%)

ALEC Alector
$29.54 /

-0.95 (-3.12%)

Conference/Events
Alector to ho ld a conference call » 04:55
07/29/21
07/29
04:55
07/29/21
04:55
ALEC

Alector

$30.49 /

+0.6 (+2.01%)

Management reviews the…

Management reviews the AL001 Phase 2 results as discussed at the recently-held Alzheimer's International Conference on a conference call to be held on July 29 at 1 pm. Webcast Link

ShowHide Related Items >><<
ALEC Alector
$30.49 /

+0.6 (+2.01%)

ALEC Alector
$30.49 /

+0.6 (+2.01%)

07/06/21 Citi
Alector price target raised to $43 from $31 at Citi
07/02/21 Goldman Sachs
GSK collaboration 'positive' for Alector, says Goldman Sachs
06/07/21 Goldman Sachs
Goldman says Biogen approval has positive read to Alector, Athira
01/15/21 BofA
Alector reinstated with a Buy at BofA
ALEC Alector
$30.49 /

+0.6 (+2.01%)

ALEC Alector
$30.49 /

+0.6 (+2.01%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.